Abstract
Placebo analgesia is mediated by both opioid and nonopioid mechanisms, but so far nothing is known about the nonopioid component. Here we show that the specific CB1 cannabinoid receptor antagonist 5-(4-chlorophenyl)-1-(2,4-dichloro-phenyl)-4-methyl-N-(piperidin-1-yl)-1H-pyrazole-3-carboxamide (rimonabant or SR141716) blocks nonopioid placebo analgesic responses but has no effect on opioid placebo responses. These findings suggest that the endocannabinoid system has a pivotal role in placebo analgesia in some circumstances when the opioid system is not involved.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Analgesics, Non-Narcotic / metabolism*
-
Chromatography, Liquid
-
Humans
-
Mass Spectrometry
-
Molecular Structure
-
Pain Threshold / physiology
-
Piperidines / chemistry
-
Piperidines / pharmacokinetics
-
Piperidines / pharmacology*
-
Placebo Effect*
-
Pyrazoles / chemistry
-
Pyrazoles / pharmacokinetics
-
Pyrazoles / pharmacology*
-
Receptor, Cannabinoid, CB1 / antagonists & inhibitors*
-
Receptor, Cannabinoid, CB1 / metabolism
-
Rimonabant
Substances
-
Analgesics, Non-Narcotic
-
Piperidines
-
Pyrazoles
-
Receptor, Cannabinoid, CB1
-
Rimonabant